References for:
Identifying Response to Acid Suppressive Therapy in Functional Dyspepsia Using a Random Starting Day Trial -- Is Gastro-Oesophageal Reflux Important?

[Aliment Pharmacol Ther 20(4):423-430, 2004. © 2004 Blackwell Publishing]

  1. Talley NJ, Colin JD, Koch KL, et al. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145-60.
  2. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastroduodenal disorders. Gut 1999; 45(Suppl 2): II37-II42.
  3. Veldhuyzen-van Zanten SJO, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996; 91: 660-73.
  4. Finney JS, Kinnersley N, Hughes M, O'Bryan-Tear CG, Lothian J. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998; 26: 312-20.
  5. Soo S, Moayyedi P, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia (Cochrane Review). The Cochrane Library 2002; 2: (Abstract).
  6. Bytzer P. H(2) receptor antagonists and prokinetics in dyspepsia: a critical review. Gut 2002; 50(Suppl. 4): IV58-IV62.
  7. Wong WM, Wong BC, Hung WK, et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51: 502-6.
  8. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055-65.
  9. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group. Gut 2000; 47: 473-80.
  10. Bolling-Sternevald E, Lauritsen K, Aalykke C, et al. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002; 37: 1395-402.
  11. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-68.
  12. Talley NJ, Weaver AL, Tesmer DL, Zinsmeister AR. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105: 1378-86.
  13. Agreus L, Talley N. Challenges in managing dyspepsia in general practice. BMJ 1997; 315: 1284-88.
  14. Madsen LG, Bytzer P. Review article: Single subject trials as a research instrument in gastrointestinal pharmacology. Aliment Pharmacol Ther 2002; 16: 189-96.
  15. Kleveland PM, Larsen S, Sandvik L, et al. The effect of cimetidine in non-ulcer dyspepsia. Experience with a multi-cross-over model. Scand J Gastroenterol 1985; 20: 19-24.
  16. Johannessen T, Fjøsne U, Kleveland PM, et al. Cimetidine responders in non-ulcer dyspepsia. Scand J Gastroenterol 1988; 23: 327-36.
  17. Farup PG, Larsen S, Ulshagen K, Osnes M. Ranitidine for non-ulcer dyspepsia. A clinical study of the symptomatic effect of ranitidine and a classification and characterization of the responders to treatment. Scand J Gastroenterol 1991; 26: 1209-16.
  18. Larsen S, Farup P, Flaten O, Osnes M. The multi-crossover model for classifying patients as responders to a given treatment. Scand J Gastroenterol 1991; 26: 763-70.
  19. Johannessen T, Petersen H, Kristensen P, et al. Cimetidine on-demand in dyspepsia. Experience with randomized controlled single-subject trials. Scand J Gastroenterol 1992; 27: 189-95.
  20. Farup PG, Hovde O, Breder O. Are frequent short gastro-oesophageal reflux episodes the cause of symptoms in patients with non-ulcer dyspepsia responding to treatment with ranitidine? Scand J Gastroenterol 1995; 30: 829-32.
  21. Farup PG, Wetterhus S, Osnes M, Ulshagen K. Ranitidine effectively relieves symptoms in a subset of patients with functional dyspepsia. Scand J Gastroenterol 1997; 32: 755-9.
  22. Bytzer P, Hansen JM, Rune S, et al. Identifying responders to acid suppression in dyspepsia using a random starting day trial. Aliment Pharmacol Ther 2000; 11: 1485-94.
  23. Veldhuyzen-van Zanten SJO, Tytgat KMAJ, Pollak PT, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol 1993; 46: 273-79.
  24. Altman D. Practical Statistics for Medical Research.1 edn. London: Chapman & Hall, 1991.
  25. Pheiffer A, Aronbayev J, Schmidt T, et al. Gastric emptying, esophageal 24-hour pH and gastric potential difference measurements in non-ulcer dyspepsia. Gastroenterol Clin Biol 1992; 16: 395-400.
  26. Klauser AG, Voderholzer WA, Knesewitsch PA, Schindlbeck NE, Muller-Lissner SA. What is behind dyspepsia? Dig Dis Sci 1993; 38: 147-54.
  27. Small PK, Loudon MA, Waldron B, Smith D, Campbell FC. Importance of reflux symptoms in functional dyspepsia. Gut 1995; 36: 189-92.
  28. Farup PG, Hovde O, Torp R, Wetterhus S. Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern. Scand J Gastroenterol 1999; 34: 575-9.
  29. Shi G, Bruley dV, Scarpignato C, Le RM, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995; 37: 457-64.
  30. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335: 205-08.
  31. Bytzer P, Hansen J, Schaffalitzky Muckadell de O. Empirical H2-blocker therapy or promt endoscopy in management of dyspepsia. Lancet 1994; 343: 811-16.
  32. Wiklund I, Glise H, Jerndal P, Carlsson J, Talley NJ. Does endoscopy have a positive impact on quality of life in dyspepsia? Gastrointest Endosc 1998; 47: 449-54.